{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:32:15Z","timestamp":1772191935947,"version":"3.50.1"},"reference-count":45,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","award":["U01FD004899"],"award-info":[{"award-number":["U01FD004899"]}],"id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013395","name":"Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>Controversy persists about bupropion XL 300\u00a0mg generic equivalence to brand product. A prospective, randomized, double\u2010blinded crossover in 70 adults with major depression in stable remission taking any bupropion XL 300\u00a0mg tested bioequivalence and therapeutic equivalence of available XL 300\u00a0mg products. After a 4\u2010week lead\u2010in on patients' existing bupropion, four 6\u2010week phases evaluated brand and three generics. Patients were uninformed of switching. Drug overencapsulation ensured blinding. There were no differences between any generic and brand, or between generics, in peak plasma concentration (C<jats:sub>max<\/jats:sub>) and area under the plasma concentration\u2010time curve over the 24\u2010hour dosing interval (AUC<jats:sub>0\u201324<\/jats:sub>) for racemic bupropion or major metabolites. All generics met formal bioequivalence criteria for bupropion and metabolites. There were no differences between generics and brand, or between generics, in depression symptoms or side effects, assessed by every 3\u2010week in\u2010person interview and daily smartphone\u2010based self\u2010report. There were no differences in patients' perceptions of bupropion products. Results show three bupropion XL 300\u00a0mg generic products are both bioequivalent and not therapeutically different from brand drug and each other.<\/jats:p>","DOI":"10.1002\/cpt.1309","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T11:37:33Z","timestamp":1542800253000},"page":"1164-1174","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial"],"prefix":"10.1111","volume":"105","author":[{"given":"Evan D.","family":"Kharasch","sequence":"first","affiliation":[{"name":"Department of Anesthesiology Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Neiner","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Washington University in St. Louis  St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Kraus","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Washington University in St. Louis  St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Blood","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Washington University in St. Louis  St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Washington University in St. Louis  St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Schweiger","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Washington University in St. Louis  St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Philip","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Biostatistics Washington University in St. Louis  St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Lenze","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Washington University in St. Louis  St. Louis Missouri USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023611"},{"key":"e_1_2_10_2_1","unstructured":"QVIA Institute for Human Data Science.Medicines use and spending in the U.S. A review of 2016 and outlook to 2021. <https:\/\/www.iqvia.com\/en\/institute\/reports\/medicines-use-and-spending-in-the-us-a-review-of-2016> (2017). Accessed August 27 2018."},{"key":"e_1_2_10_3_1","unstructured":"Association for Accessible Medicines.Generic drug access and savings in the United States. <https:\/\/www.accessiblemeds.org\/resources\/blog\/2017-generic-drug-access-and-savings-us-report> (2017). Accessed August 27 2018."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0713"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00210.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2015.08.017"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052619"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09020186"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1212969"},{"key":"e_1_2_10_10_1","unstructured":"Food and Drug Administration (FDA) Center for Drug Evaluation and Research.Update: Budeprion XL 300\u00a0mg not therapeutically equivalent to Wellbutrin XL 300\u00a0mg. <http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm322161> (2012). Accessed August 27 2018."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316629071"},{"key":"e_1_2_10_12_1","unstructured":"US Food and Drug Administration (FDA).Review of therapeutic equivalence generic Bupropion XL 300\u00a0mg and Wellbutrin XL 300\u00a0mg. <http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm153270> archived at <https:\/\/wayback.archive-it.org\/7993\/20171102213516\/>; <https:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm153270.htm> (2012). Accessed August 27 2018."},{"key":"e_1_2_10_13_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research.Guidance for industry: statistical approaches to establishing bioequivalence. <https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070244.pdf> (2001). Accessed August 27 2018."},{"key":"e_1_2_10_14_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research.Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products \u2010 general considerations. <https:\/\/www.ipqpubs.com\/wp-content\/uploads\/2014\/04\/BABEOld.pdf> (2003). Accessed August 27 2018."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9396-8"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2015.11.005"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)02010-7"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.001313"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm1003232"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.068932"},{"key":"e_1_2_10_21_1","unstructured":"GlaxoSmithKline (GSK) reviews novel therapeutics for CNS disorders and confirms strong pipeline momentum(Press Release November 23 2004) 2004 pp <https:\/\/web.archive.org\/web\/20070928041150>; <http:\/\/www.biospace.com\/news_story.aspx?StoryID=18222420&full=1>. Accessed August 27 2018."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08722"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1176\/ajp.156.8.1177","article-title":"Three\u2010year outcomes of maintenance nortriptyline treatment in late\u2010life depression: a study of two fixed plasma levels","volume":"156","author":"Reynolds C.F.","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0017075"},{"key":"e_1_2_10_25_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research.Update: bupropion hydrochloride extended\u2010release 300\u00a0mg bioequivalence studies. <https:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm322161.htm> (2013). Accessed August 27 2018."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-6-200009190-00014"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3612-7"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.1688"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.1720"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/009885881203800403"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.126705"},{"key":"e_1_2_10_32_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research.Orange book: approved drug products with therapeutic equivalence evaluations. <http:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/default.cfm> (2013). Accessed August 27 2018."},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0048-x"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q349"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00350-13"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2011.11.022"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.591"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.04.032"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.02.032"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.05.036"},{"key":"e_1_2_10_41_1","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research U.S. Department of Health and Human Services.Guidance for industry: bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. <https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm377465.pdf> (2013). Accessed August 27 2018."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.032532"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.061960"},{"key":"e_1_2_10_45_1","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research Division of Product Quality Research.Bioequivalence evaluation of innovator and generic bupropion XL products: Final report. <http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM323471.pdf> (2012). Accessed August 16 2018."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1309","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:35:59Z","timestamp":1699364159000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1002\/cpt.1309"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1309","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"2018-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}